Harms and benefits of cervical cancer screening among non-attenders in Switzerland: The transition towards HPV-based screening.
Cervical cancer screening
Developed countries
HPV testing
Harms
Screening frequency
Self-HPV
Journal
Preventive medicine reports
ISSN: 2211-3355
Titre abrégé: Prev Med Rep
Pays: United States
ID NLM: 101643766
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
24
07
2022
accepted:
26
07
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
13
8
2022
Statut:
epublish
Résumé
Human papillomavirus (HPV) testing is replacing cytological screening for cervical cancer. Our aim was to assess the expected benefits and harms of different cervical screening strategies. This study is sub-analysis of a previous cost-effectiveness study with a target population of unscreened women without cervical cancer aged ≥ 25 years. A recursive decision-tree with one-year cycles was used to model the life-long natural HPV history. Markov cohort simulations were used to assess the expected outcomes from the model. The outcomes of three strategies were compared with the absence of screening: HPV-testing on self-collected vaginal samples (Self-HPV) followed by colposcopy (Self-HPV/colpo), Self-HPV and triage with cytology (Self-HPV/PAP), cytology and triage with HPV (PAP/HPV). All screening strategies resulted in reductions in cancer cases and deaths. Self-HPV strategies were associated with a lower cancer incidence and mortality life-long, not only when performed every 3 years but also when Self-HPV was performed every 5 years vs cytology every 3 years. The gain in life expectancy obtained was 82 days with Self-HPV/colpo, 81 days with Self-HPV/PAP and 75 days with PAP/HPV compared to no screening. The number of lifetime total visits was greater with PAP/HPV compared with the Self-HPV strategies (13.13 vs < 3). The number of conizations remained relatively stable with the change of screening frequency and strategy. Self-HPV may represent a reasonable balance of harms and benefits when performed every 5 years compared to cytology every 3 years. Self-HPV/PAP yielded the most efficient harm to benefit ratio when using colposcopy as a proxy for harms.
Identifiants
pubmed: 35959498
doi: 10.1016/j.pmedr.2022.101929
pii: S2211-3355(22)00236-4
pmc: PMC9357843
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101929Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Acta Obstet Gynecol Scand. 2021 Mar;100(3):394-402
pubmed: 33566361
Gynecol Oncol. 2007 May;105(2):530-5
pubmed: 17335880
Am J Epidemiol. 2000 Jun 15;151(12):1158-71
pubmed: 10905528
Psychooncology. 2012 Oct;21(10):1071-81
pubmed: 21695747
BMJ. 2010 Feb 23;340:b4491
pubmed: 20179125
JAMA. 2018 Aug 21;320(7):706-714
pubmed: 30140882
MDM Policy Pract. 2020 Aug 19;5(2):2381468320952409
pubmed: 32885045
JAMA Intern Med. 2019 Jul 1;179(7):867-878
pubmed: 31081851
Br J Cancer. 2017 May 23;116(11):1382-1388
pubmed: 28427086
Br J Obstet Gynaecol. 1990 Sep;97(9):859-61
pubmed: 2242376
J Natl Cancer Inst. 2012 Feb 8;104(3):178-88
pubmed: 22271765
BMJ. 2004 May 29;328(7451):1293
pubmed: 15166066
Br J Cancer. 2004 Aug 2;91(3):530-6
pubmed: 15266332
Gynecol Oncol. 2019 Apr;153(1):92-99
pubmed: 30718124
BJOG. 2013 Sep;120(10):1260-7; discussion 1267-8
pubmed: 23786222
Am J Obstet Gynecol. 2021 Feb;224(2):200.e1-200.e9
pubmed: 32800820
Int J Cancer. 2018 Aug 15;143(4):735-745
pubmed: 29341110
J Gen Intern Med. 2020 Mar;35(3):956-958
pubmed: 31313121
BMC Public Health. 2020 Oct 7;20(1):1517
pubmed: 33028278
Br J Cancer. 2005 Sep 5;93(5):575-81
pubmed: 16136031
J Obstet Gynaecol Can. 2012 May;34(5):443-452
pubmed: 22555137
J Natl Cancer Inst. 2006 Jun 7;98(11):765-74
pubmed: 16757701
BMJ. 2008 Sep 18;337:a1284
pubmed: 18801868
Discov Med. 2012 Aug;14(75):125-31
pubmed: 22935209
Eur J Public Health. 2017 Feb 1;27(1):167-173
pubmed: 28177486
BJOG. 2012 Jul;119(8):936-44
pubmed: 22568482
J Low Genit Tract Dis. 2016 Apr;20(2):135-8
pubmed: 26735148
BJOG. 2009 Oct;116(11):1506-14
pubmed: 19583712
Patient Prefer Adherence. 2019 Jul 01;13:1005-1017
pubmed: 31303748
Int J Cancer. 2017 Mar 1;140(5):1215-1222
pubmed: 27864938
Int J Cancer. 2020 Dec 1;147(11):3068-3074
pubmed: 32484236
Lancet. 2014 Feb 8;383(9916):524-32
pubmed: 24192252
Vaccine. 2012 Nov 20;30 Suppl 5:F88-99
pubmed: 23199969
Lancet. 2006 Feb 11;367(9509):489-98
pubmed: 16473126